Skip to main content
S&P 5007,525.09-0.80%DOW51,334.38-1.46%NASDAQ25,867.46-0.44%BTC$75,813.00-0.15%ETH$2,403.55+0.02%GOLD$4,310.30-0.52%OIL$102.53-3.12%
Smart Investors Daily
TC

NASDAQ · TCRR

TCR2 Therapeutics Inc.

Healthcare · Biotechnology

$1.48

Up+$0.00 (+0.00%)

Updated Sep 16, 2026, 7:18 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
58.11M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
— – —
Volume
3.75M
Avg. volume
325.4K

Price performance

TCRR price history

1M range · 0 trading sessions · Daily adjusted prices

TCRR does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest TCRR news

The latest Smart Investors Daily articles mentioning TCRR.

Stock researchCompany · Overview

TCRR research

Overview

Company profile and research snapshot.

Company profile

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
TCRR recent ratings
DateFirmRatingTarget
Mar 24, 2023MizuhoNeutral—
Mar 23, 2023EF HuttonHold—
Mar 9, 2023JefferiesUnderperform—
Mar 8, 2023Truist SecuritiesHold—
Mar 7, 2023HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · May 11, 2023

Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Sensus Healthcare The Trade: Sensus Healthcare, Inc. (NASDAQ: SRTS) Director Samuel O'Rear acquired a total 20,000 shares an average price of ...

GlobeNewswire Inc. · May 11, 2023

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Benzinga · May 8, 2023

Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Ribbon Communications The Trade: Ribbon Communications Inc. (NASDAQ: RBBN) Preseident and CEO William Bruce McClelland acquired a total 10,000 shares an average price of $2.60. To acquire these shares, it cost around $26 thousand. The company’s EVP ...

GlobeNewswire Inc. · Apr 3, 2023

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2’s common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees’ acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By